As the DeepSeek-driven sell-off in US AI stocks started to fade, China is claiming advances in another new-age technology that can impact quantum computing stocks globally. Origin Quantum Computing Technology’s prototype received over 20 million remote visits worldwide, marking a major milestone in the mainland’s quantum computing landscape.
Although China has been viewed as lagging behind the US in quantum computing, it could be leading the race when it comes to quantum communications (quantum networking). China has consistently tested secure quantum communications in fiberoptic and satellite networks.
Elsewhere, physicists working in Google’s laboratory developed a new digital-analog quantum simulator that can study and calculate complex physical processes with unprecedented precision. The milestone has the potential to solve different challenges in diverse fields, from solid-state physics to astrophysics.
“Our research demonstrates that it is possible to create superconducting analog-digital quantum processors on a chip and that these are suitable as quantum simulators,” said Andreas Läuchli, one of the theoretical scientists involved in the breakthrough.
We selected AI stocks by reviewing news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
The trading floor of Pacific Investment Management Company LLC with traders focusing on the global fixed income markets.
10. Safe Pro Group Inc. (NASDAQ:SPAI)
Number of Hedge Fund Holders: N/A
Safe Pro Group Inc. (NASDAQ:SPAI) offers AI solutions powered by proprietary ML, computer vision technology, and Amazon Web Services for drone imagery processing to rapidly identify explosives threats.
On February 18th, Safe Pro Group Inc. (NASDAQ:SPAI) announced that its Safe Pro AI subsidiary will showcase its patented Drone AI-Powered SpotlightAITM technology at the XPONENTIAL Europe trade fair for autonomous technologies and robotics, which is scheduled between February 18th and 20th in Germany. Safe Pro AI’s lead software and AI developer, Gabriel Steinberg, will highlight how the company’s AI-powered mine and UXO detection capabilities could aid international peacekeeping forces by facilitating safer operations within any potential DMZ. Safe Pro’s proprietary AI models have analyzed over 945,000 drone images in Ukraine, identifying over 19,000 explosive remnants of war across 4,355 hectares.
“We are honored to present our disruptive American AI capabilities to leading international authorities at this pivotal point in time as global leaders are meeting in Europe to discuss the future security needs of Ukraine. Being chosen to present at flagship global events such as XPONENTIAL affords us the opportunity to bring greater attention to our firm and how our technology can support our allied nations in their global missions.”
-said Dan Erdberg, Chairman and CEO of Safe Pro Group Inc.
9. Predictive Oncology Inc. (NASDAQ:POAI)
Number of Hedge Fund Holders: N/A
Predictive Oncology Inc. (NASDAQ:POAI) uses AI and ML to accelerate early drug discovery and facilitate drug development to benefit cancer patients. The company’s AI platform, PEDAL, can forecast the efficacy of medicines on tumor samples with a 92% accuracy, enabling informed selection of drug/tumor type combinations for in-vitro testing.
On February 18th, Predictive Oncology Inc. (NASDAQ:POAI) announced that it built a registry of promising candidates using drug datasets abandoned or discontinued by pharma companies that can be repurposed to achieve efficacy in treating ovarian, colon, and breast cancer.
“Early results show that by running our platform for just eight weeks, we were able to identify compounds for use in one or more tumor types. By precisely measuring only 92 combinations of laboratory experiments on patient tumor samples, the predictive model was capable of making an additional 964 confident predictions, covering a total of 79% of all possible experiments,” said Dr. Arlette Uihlein, Medical Director at Predictive Oncology Inc. “Our active learning AI platform enabled us to efficiently and confidently predict an additional 10x the number of measured experiments, eliminating at least 18 months of wet lab testing and identifying two drugs as having very promising results for use in one or more tumor types. Both of these drugs outperformed a known standard of care drug used to treat colon cancer.”
